Mr. Aida has more than 4 decades of pharmaceutical industry experience.
He started his career with Zeneca and then AstraZeneca, where he served as leader of various departments including sales/distribution, marketing and clinical development. One of his most notable achievements while at AstraZeneca Japan was leading the successful development and regulatory approval of IRESSA® (gefinitib), an EGFR inhibitor for the treatment of NSCLC. IRESSA® was the first innovative EGFR inhibitor which obtained approval in Japan before the U.S.
After leaving AstraZeneca, Mr. Aida spent 8 years at Quintiles/IQVIA in Japan as head of clinical operations.
Following retirement from Quintiles 5 years ago, Mr. Aida started a consultancy to support small western biotech companies seeking to enter the Japan market.
Mr. Aida earned his university degree at Kanazawa University.